WVE$6.885
Chart
Performance
Key Stats
AI WVE Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldWave Life Sciences operates in the promising field of RNA therapeutics, with a strong scientific platform. However, recent performance, consistent losses, and unproven commercialization necessitate a cautious approach. The stock exhibits mixed technical signals.
Thematic
Wave Life Sciences is positioned within the high-growth RNA therapeutics sector, which has seen significant advancements and investment. The company's PRISM platform, focused on a wide range of disorders, aligns with key healthcare trends.
Fundamental
Wave Life Sciences exhibits significant operational losses and negative earnings, characteristic of a clinical-stage biotechnology company. While its cash position is substantial, revenue generation is minimal, and profitability remains elusive.
Technical
The stock is trading within a defined range, with mixed signals from technical indicators. While recent performance shows a rebound, it is still significantly below its 52-week high, and momentum indicators are largely neutral to cautious.
| Factor | Score |
|---|---|
| RNA Therapeutics Advancement | 90 |
| Target Disease Areas | 85 |
| Biotechnology Innovation | 80 |
| Partnerships & Collaborations | 70 |
| Biotech Regulatory Landscape | 50 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 20 |
| Balance Sheet Health | 70 |
| Cash Flow | 15 |
| Debt Level | 80 |
| Factor | Score |
|---|---|
| Trend Analysis | 60 |
| Momentum | 65 |
| Volume Analysis | 50 |
| Price Range | 40 |
| Recent Performance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (9)
Positive Short-Term Momentum
The stock has shown strong short-term performance with a 19.35% return in the last month, indicating positive investor sentiment and recent buying activity.
Short-term Moving Average Buy Signals
Several short-term moving averages (10-day EMA, 20-day EMA, 30-day EMA, 50-day EMA, 100-day EMA, 200-day EMA) are indicating a 'Buy', suggesting upward price momentum on shorter timeframes.
Bearish Points (10)
Recent Price Decline
The stock is down -1.99% in the current trading session and has a significant negative year-to-date return of -37.01%, indicating a bearish trend.
Inconsistent EPS Performance
There have been significant EPS misses in several recent quarters (e.g., Q4 2024 with a -65.88% surprise), indicating challenges in meeting earnings expectations.
Calendar
July 2025
30
Next Earnings Date
H: $-0.24
A: $-0.28
L: $-0.31
H: 18.00M
A: 11.52M
L: 5.00M
Profile
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Seasonals
Price Target
20.38 USD
The 39 analysts offering 1 year price forecasts for WVE have a max estimate of 36.00 and a min estimate of 9.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Worthington Steel was spun off from Worthington Industries (now Worthington Enterprises, WVE) in December 2023. It continues the company's legacy steel processing business, making it the most directly related entity.
Weight: 98
As the largest metals service center company, Reliance Steel & Aluminum directly competes with or complements Worthington Enterprises' steel processing and metal distribution operations.
Weight: 95
Nucor is a major integrated steel producer and fabricator, serving as both a potential supplier of raw steel and a competitor in various steel products and value-added services.
Weight: 93
Steel Dynamics is another leading diversified steel producer and metals recycler, with operations that overlap Worthington Enterprises' in steel manufacturing and fabrication.